{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-121828","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.769498+00:00","generated_at":"2026-05-16T12:55:15.403635+00:00","sec_items":["1.01","3.02","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company","bullets":["Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.","Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.","Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.","Expected close Q2 2026; post-close board and officers designated by Yarrow."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-121828","json":"https://secwatch.observer/filing/0001104659-25-121828.json","markdown":"https://secwatch.observer/filing/0001104659-25-121828.md","text":"https://secwatch.observer/filing/0001104659-25-121828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/0001104659-25-121828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925121828/tm2533624d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:55:15.403635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}